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Abstract 
Isolating, purifying, and identifying proteins in complex biological matrices is often 
difficult, time consuming, and unreliable.  Herein we describe a rapid screening technique for 
proteins in biological matrices that combines selective protein isolation with direct surface 
enhanced Raman spectroscopy (SERS) detection. Magnetic core gold nanoparticles were 
synthesised, characterised, and subsequently functionalized with recombinant human 
erythropoietin (rHuEPO)-specific antibody. The functionalized nanoparticles were used to 
capture rHuEPO from horse blood plasma within 15 minutes. The selective binding between 
the protein and the functionalized nanoparticles was monitored by SERS. The purified 
protein was then released from the nanoparticles’ surface and directly spectroscopically 
identified on a commercial nanopillar SERS substrate. ELISA independently confirmed the 
SERS identification and quantified the released rHuEPO. Finally, the direct SERS detection 
of the extracted protein was successfully demonstrated for in-field screening by a handheld 
Raman spectrometer within 1 minute sample measurement time.   
 
 
 
 
Key words 
Selective isolation, Label-free SERS, Magnetic core gold nanoparticles, Erythropoietin, In-
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Background 
The efficient and accurate analysis of biomolecules found in complex biological matrices 
like blood or urine is essential for many applications, including protein characterization, 
clinical diagnostics, and drug dosing protein analysis, but current methods are usually 
expensive and time consuming [1-4].  Simultaneous methods for sample separation and 
detection must exhibit sufficiently high resolution, high sensitivity and wide dynamic range 
to detect low concentrations of proteins [5-7].  Ideally, these methods should also be easy to 
perform, rapid, non-toxic, environment-friendly, and cost-effective.  No current protein 
detection technique meets all these demands [5-7].  Although mass spectrometry (MS) is 
sensitive and accurate for the analysis of proteins [8, 9], it is relatively expensive, requires 
specialised skills, and cannot be field adapted.   
Enzyme-linked immunosorbent assay (ELISA) is a widely used technique in protein 
analysis. ELISA methods fall in two categories, direct and indirect. The direct methods use 
only one primary antibody while the indirect methods use primary and secondary antibodies. 
Direct ELISA methods have significant disadvantages such as: 1) the antibody’s immune-
reactivity is adversely affected by labelling with enzymes or tags; 2) labelling the used 
antibody is time-consuming and expensive; 3) there is only a limited choice of antibody 
labels that can be used from one experiment to another; 4) the signal amplification is modest. 
Indirect ELISA methods suffer from other disadvantages such as the long analysis time, due 
to the introduction of extra incubation steps in the procedure, and cross-reactivity with the 
secondary antibody, which result in nonspecific signals [10]. 
Surface-enhanced Raman spectroscopy (SERS), which characterises molecules by their 
vibrational fingerprint, is a rapidly emerging technique for the detection of biomolecules [11-
12].  In SERS, the surface plasmon resonance (SPR) of a nanostructured noble metal surface 
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enhances the oscillating electric field of incident light [13]. This near-field enhancement 
increases the Raman signal of analyte molecules that are in close proximity to the metal 
surface by factors as high as 10
6–108 relative to the unenhanced Raman signal [13-15], 
making it useful for ultra-trace detection and potentially allowing for single-molecule 
detection [16, 17].   
SERS strategies may be employed to either directly or indirectly detect biomolecules. In 
the direct method, a biological sample is loaded onto a noble metal substrate and directly 
analysed by SERS to acquire the Raman signature of the biomolecule [18-20]. SERS 
provides direct structural information about the bound target molecule and identifies 
qualitative differences between similar samples. However, this approach lacks specificity and 
the Raman spectroscopic features other molecules present in a complex biological matrix can 
obscure the Raman characteristics of the target analyte.  For this reason, extensive isolation 
and clean-up procedures are required prior to direct SERS detection [21]. By comparison, 
SERS may indirectly detect biomolecules by attaching a Raman-active dye to the metal 
SERS substrate [20, 22]. The substrate’s surface carrying the Raman dye is then pacified with 
a protective layer (e.g. silica shell) to prevent the non-specific binding of potentially 
interfering biomolecules in a complex biological matrix. Analyte-specific recognition 
molecules, such as antibodies or aptamers, are attached to the SERS substrate to provide 
target specificity [20]. However, indirect SERS detection does not detect the target 
biomolecule itself, but only detects the SERS spectrum of the Raman dye [21].  Specific 
recognition of the target analyte by the antibody or aptamer must be assumed to occur 
without significant cross reactivity. 
We recently demonstrated a hybrid approach for label-free indirect SERS detection of 
proteins, in which a SERS substrate was functionalized with a protein-specific antibody or 
aptamer for target specificity, but no Raman dye was attached to the SERS substrate [21, 22]. 
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Instead, the SERS spectra of surface-bound antibody or aptamer were compared before and 
after the binding of the target protein.  Differences in features between the spectra were used 
to identify the target protein in aqueous and biological samples. 
Erythropoietin (EPO) is a glycoprotein hormone used in the regulation of erythropoiesis 
and is involved as a signalling protein in the production of red blood cells in bone marrow 
[23]. Sports doping with exogenous rHuEPO increases oxygen capacity and leads to 
enhanced aerobic performance by athletes. The short biological half-life of rHuEPO makes it 
only detectable in urine for 3–7 days [24–26]. Recent doping regimens, in which micro-doses 
of rHuEPO (approximately 20–25 IU/kg) are administered to avoid random detection by anti-
doping authorities, have reduced the rHuEPO detection window to only 12–18 hours [27].  
The standard protocol currently used to detect rHuEPO doping in competitive sports, 
isoelectric focusing and double blotting [28], takes several days to perform in a laboratory-
based environment and requires skilled technicians, complex procedures, and expensive 
equipment. To detect rHuEPO doping in sports environment, a reliable rHuEPO screening 
technique is required that is both rapid and field adaptable. In order to identify rHuEPO in 
urine and blood, the existing reference techniques attempt direct detection of the substance 
and/or its metabolite in its original biological matrix [7, 29].  This requires extensive clean-up 
procedures to isolate the protein from the biological matrix of origin prior to the 
measurement.  
Here we introduce a modified approach for simplified selective isolation and label-free 
direct SERS detection of rHuEPO to demonstrate the utility of this technique for detecting 
biomolecules in complex biological matrices. We first developed magnetic core gold 
nanoparticles and functionalized their surfaces with rHuEPO-specific antibodies to create a 
rHuEPO-specific recognition layer. The remaining bare gold surface on the nanoparticles 
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surface was pacified by backfilling with an alkane thiol to block non-specific binding of 
potentially interfering molecules. The functionalized nanoparticles selectively captured 
rHuEPO from spiked horse plasma. The binding event between rHuEPO and the 
functionalized nanoparticles was monitored by SERS [30]. To confirm the selective capture 
of rHuEPO, as well as to directly detect the its Raman fingerprint, the bound rHuEPO 
molecules were released from the extractor nanoparticles, loaded onto a gold-coated silicon 
nanopillar substrate and characterised by SERS.  To cross-validate our methodology, 
rHuEPO that had been captured by our functionalized nanoparticles was screened by an 
independent laboratory using rHuEPO-specific ELISA. Finally, to demonstrate applicability 
of this new method for the in-field rapid screening of rHuEPO, we directly acquired the 
SERS spectrum of the captured and released rHuEPO using a handheld Raman device and 
compared it to a standard rHuEPO SERS spectrum.  
The significant advantages of the protein analysis methodology that we describe here 
include: 1) the rapid and selective isolation of the target proteins directly from a complex 
biological matrix; 2) the ability to monitor the selective antibody-antigen binding event by 
SERS; 3) the ability to directly detect the native protein’s Raman fingerprint by SERS; and 4) 
the applicability of this technique to the rapid detection of proteins in the field. 
Methods 
Chemicals and reagents 
Recombinant human erythropoietin international standard (rHuEPO IS, 3
rd
 International 
Reference Preparation) was sourced from the National Institute for Biological Standards and 
Control, UK. 7D3 mouse monoclonal anti-human erythropoietin antibody was purchased 
from MAIIA Diagnostics, Uppsala, Sweden. Gold (III) chloride (HAuCl4), phosphate 
buffered saline, bovine serum albumin, sodium borohydride (NaBH4, 99%), trisodium citrate 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
7 
 
(Na3C6H5O7· 2H2O), ferrous chloride (FeCl2. 4H2O), ferric chloride (FeCl3. 6H2O), nitric 
acid and sodium hydroxide were of analytical grade and purchased from Sigma-Aldrich 
(USA). Gravity flow size-exclusion columns (illustra NAP-5) were obtained from GE 
Healthcare Life Sciences (AU). Deionized water (ultrapure Millipore filtered, 18.2 
MΩ.cm@25˚C) was used in all preparations. All glassware was cleaned with aqua regia and 
thoroughly rinsed with deionized water prior to use. Quantikine IVD human erythropoietin 
ELISA kit from R&D Systems (USA, catalogue No DEP00) was used for the detection of 
rHuEPO in horse plasma.  
Synthesis of iron oxide nanoparticles 
To develop the magnetic iron oxide cores, Fe3O4 nanoparticles were first prepared by 
precipitation, and then chemically oxidized to γ-Fe2O3 [31, 32]. Briefly, FeCl3.6H2O (10 
mmol) and FeCl2.4H2O (5 mmol) were dissolved in dilute hydrochloric acid solution (12.5 
mL, 0.36 M) with magnetic stirring. The developed clear yellow solution was then added 
dropwise to NaOH solution (125 mL, 1.5 M) with vigorous stirring where a black precipitate 
was immediately formed. The resulting mixture was stirred for 10 minutes after complete 
addition. The formed precipitate was then collected using strong permanent magnet. To 
neutralize the pH of the precipitate, it was rinsed with dilute hydrochloric acid solution (250 
mL total, 0.01 M). Finally, the precipitate was washed several times with deionized water. 
The washed precipitate was then re-suspended in dilute nitric acid solution (125 mL, 0.01 M), 
boiled to reflux for one hour, then cooled to room temperature. The resulting iron oxide 
nanoparticles were collected using a magnet and rinsed several times with deionized water to 
neutralize the medium.  The clean brown-coloured product was resuspended in 50 mL of 
deionized water, and the concentration was determined gravimetrically to be 0.177 M.  
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Development of magnetic core gold nanoparticles 
To develop a gold shell onto the iron oxide nanoparticle surface, a method described by 
Tamer et. al [33] was adopted with modifications. 0.6 mL of the iron oxide nanoparticle 
colloid (0.177 M) was transferred into a 100 mL volumetric flask and diluted with deionized 
water. 19 mL of the resulting solution was transferred to another round-bottomed flask. 
HAuCl4 (0.5 mL, 1%) was then added and the resulting mixture diluted to 100 mL with 
deionized water. To reduce gold atoms onto the iron oxide nanoparticles’ surface, freshly 
prepared NaBH4 solution (0.2 mL, 0.05 M) was added to the mixture, followed by 5 
successive additions of 0.1 mL NaBH4 (0.05 M). The mixture was vigorously swirled for 10 
minutes after each addition. The mixture was then heated to boil and 3 mL of sodium citrate 
solution (0.1 M) was added dropwise to produce a pink coloured colloid. The formed 
magnetic core gold nanoparticles were removed from the reaction mixture using a magnet. 
The nanoparticles were then washed several times with D.I water and finally resuspended in 
4 mL of D.I water.  
Development of antibody-functionalized magnetic core gold nanoparticles 
To attach the 7D3 anti rHuEPO antibodies to the gold surface of the magnetic core gold 
nanoparticles, cysteamine was used as a linker. The amine group of cysteamine was utilized 
to form amide bond with the C-terminus of the antibody structure [34]. For this purpose, 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide solution (EDAC, 0.2 M) and N-
hydroxysuccinimide solution (NHS, 0.1 M) were prepared in PBS (pH 7.4) and used to 
activate the -COOH groups of the 7D3 anti-rHuEPO antibody [34]. 50 µL of both EDAC and 
NHS solutions were added to a LoBind vial and vortexed for 15 minutes. 100 µL of aqueous 
cysteamine (3x10
-5
 M) was then added to the vial and mixed for another 15 minutes. 50 µL of 
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the 7D3 anti-rHuEPO antibody (2x10
-5
 M in PBS, pH 7.4) was then added to the mixture in 
ten equal volumes with 2 minutes vortex between additions. After complete mixing, the 
solution was allowed to stand for 5 hours under dark conditions at 4˚C. After this time, the 
reaction mixture was purified using a gravity flow size-exclusion column to obtain the 
cysteamine-bound 7D3 antibody.  
 To attach the cysteamine-bound 7D3 antibody to the magnetic core gold nanoparticles, 
100 µL of the nanoparticles were mixed with 50 µL of the antibody in a LoBind Eppendorf 
vial and left to form Au-S bonds between the thiol (-SH) group of cysteamine-bound 
antibodies and the gold surface of the nanoparticles overnight at 4˚C. To prevent non-specific 
binding of interfering analytes and enhance the selectivity of the functionalized nanoparticles 
towards the target protein, any remaining bare sites (i.e. gold surface areas that were not 
occupied by the antibodies) were backfilled by adding 15 µL of 1-butanethiol (1x10
-6
 M in 
PBS, pH 7.4) and allowing the mixture to stand for at 1 hour [35, 36]. The backfilled 
functionalized magnetic core gold nanoparticles were then separated using a magnet, 
resuspended in 100 µL PBS (pH 7.4), and stored in a refrigerator at 4˚C.  
Selective isolation and SERS monitoring of rHuEPO binding to functionalized nanoparticles 
The backfilled functionalized nanoparticles were used to selectively capture rHuEPO from 
aqueous solution. An aqueous standard of rHuEPO (1.1 x10
-8
 M in PBS buffer, pH 7.4) was 
added to the functionalized nanoparticle colloid in the ratio of 1:10 v/v. The mixture was left 
to stand for 15 minutes to complete binding between the antibody and rHuEPO. The protein-
bearing functionalized nanoparticles were then collected using a magnet and washed several 
times with PBS buffer (pH 7.4) to remove unbound protein. The protein-bearing 
functionalized nanoparticles were then screened using SERS and the acquired spectrum 
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compared to that of the functionalized nanoparticles prior to their interaction with the 
rHuEPO. 
For the isolation of rHuEPO from a biological matrix, rHuEPO spiked horse plasma was 
mixed with the backfilled functionalized nanoparticles and PBS buffer (pH 7.4) in the ratio of 
1: 5: 50 respectively, to a total volume of 100 μL. The final concentration of rHuEPO in the 
mixture was 1 nM. The mixture was then left to stand for 15 minutes to the complete binding 
between the nanoparticles and rHuEPO. The nanoparticles were then magnetically removed 
from the matrix and rinsed several times with PBS buffer (pH 7.4) to remove any unbound 
proteins.  
Blank horse plasma samples were donated by Biological Research Unit, Racing Analytical 
Services Ltd, Melbourne. The samples were collected under the Melbourne lab protocols and 
ethical clearances, arrangements and protocols are all maintained by this lab. The samples 
were also shipped under their lab protocols for shipping biological specimens. The samples 
were received at QUT and used as a matrix for Raman testing. 
Direct SERS detection and ELISA assay of extracted rHuEPO from horse plasma 
For the direct SERS detection of rHuEPO from spiked horse plasma, the protein-bearing 
functionalized nanoparticles were reconstituted in 100 μL of N-acetyl glucosamine buffer to 
release the captured protein [37]. The released protein solution was then loaded onto a 
preconditioned gravity flow size exclusion column for 5 minutes to remove the buffer. The 
protein was eluted off the column using 500 μL of deionized water. 10 µL of the clean 
rHuEPO solution was then loaded onto gold-coated silicon nanopillars SERS substrate [38, 
39] and directly screened by SERS for 1 minute using the Renishaw inVia Raman 
Microscope as well as a handheld Raman spectrometer (ID Raman, ocean optics, USA).  
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For cross validation of the SERS measurements, aliquots of the extracted rHuEPO were 
submitted to independent screening by Solid Phase Sandwich ELISA [40] at the research 
unit, Racing Analytical Services Ltd, Melbourne, Australia.  
Instrumentation and spectroscopic measurements  
The iron oxide nanoparticles and the magnetic core gold nanoparticles were characterised 
by transmission electron microscopy (TEM) [JEOLJEM-1400 (JEOL, USA)] and UV–visible 
spectroscopy [Cary 100 spectrophotometer (Agilent Technologies, USA)]. For the 
determination of the iron oxide phase, samples were dried and prepared as a thin film, then 
the X-Ray diffraction patterns were collected using a Philips X'pert wide angle X-Ray 
diffractometer operating in step scan mode, with Co Kα radiation (1.7903 Å). Patterns were 
collected in the range 10 to 80° 2θ with a step size of 0.02° and a rate of 30s per step. The 
XRD patterns were matched with ICSD reference patterns using the software package 
HighScore Plus. 
Raman spectra were collected on the Renishaw inVia Raman Microscope using an 
excitation wavelength of 785 nm and 0.5% of maximum (450mW) laser power. Spectra were 
collected by a 50x objective lens over a wavelength range from 300 cm
-1
 to 1800 cm
-1
 using 
10 accumulations (1 second exposure time per accumulation). At least 30 spots, on various 
locations of the SERS substrate, were screened per each submitted sample. 
For SERS measurement using the handheld IDRaman Mini, the sample was screened in the 
Raster Orbital Scanning (ROS) mode using 785 nm excitation wavelength and 40 
accumulations per minute per sample [41].  
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Results  
Synthesis and characterization of magnetic core gold nanoparticles 
The attraction towards magnetic core gold nanoparticle synthesis is due to their novel 
properties and potential applications in various fields such as cellular hyperthermia [42], 
magnetic resonance imaging [43], drug and gene delivery [44], as well as biotechnology [45]. 
In these applications, the iron oxide core performs as a giant paramagnetic atom with a fast 
response to the applied magnetic field especially when the size of the core is between 5 and 
20 nm [46].  Gold is chemically stable, biocompatible, and has excellent plasmonic properties 
for SERS [47]. Due to the surface chemistry of gold, the development of gold shells onto the 
iron oxide nanoparticles surface facilitates the functionalization of the nanoparticles with 
EPO-specific antibody [48] as well as enhances the stability of the magnetic core of the 
nanoparticles [31-32]. 
In this work, γ-Fe2O3 nanoparticles were synthesised for the deposition of a gold shell [51, 
52]. The synthesized nanoparticles were spherical in shape with a mean size distribution of 
10±2 nm as characterized by TEM (Fig 1a). The phase of the γ-Fe2O3 nanoparticles was 
confirmed by X-ray diffraction (Fig. 2). Both the magnetite and maghemite phases have the 
same spinel structure as well as very similar lattice parameters. The peaks at diffraction 
angles (2θ) of 35.3°, 41.7°, 50.8,° 67.7°, and 74.9° degrees indicate that the pattern could be 
indexed to a cubic structure of either magnetite or maghemite. The peaks at 24.7° and 21.3° 
also suggest the presence of both magnetite and maghemite phases of the iron oxide. 
However, the high intensity of the peak at 41.7 indicates that the iron oxide nanoparticles 
exist predominantly in the maghemite phase [46].  
To develop a gold shell onto the surface of the magnetic nanoparticles, iterative reduction 
of HAuCl4 was carried out using sodium borohydride to initially nucleate gold onto the iron 
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oxide nanoparticles surface. Subsequent sodium citrate reduction of Au
3+
 ions to Au 
expanded the nucleated gold into a shell around the magnetic core. The resulting magnetic 
core gold nanoparticles were spherical with an average size of 15±6 nm as indicated by TEM 
(Fig.1b). The plasmonic properties of the magnetic core gold nanoparticles were confirmed 
by a characteristic plasmon band at 530 nm observed by UV–visible spectroscopy (Fig. 3). 
Selective isolation and SERS monitoring of rHuEPO binding to magnetic core gold 
nanoparticles 
The magnetic core gold nanoparticles were then functionalized with 7D3 anti-rHuEPO 
antibodies and used for the selective isolation of rHuEPO. Functionalizing a gold 
nanoparticle surface with antibodies has been previously described [34], where cysteamine 
was used to link an active carboxylic acid terminus, of Aflatoxin B1 antibody (via an amide 
bond) to the gold surface. Unfortunately, cysteamine on a gold surface may adopt a gauche 
configuration in which the cysteamine molecule binds to the gold nanoparticles from both its 
thiol and amine ends [49]. In this conformation, the amine group of cysteamine would not be 
available to bind the antibody [50]. To maximize the number of antibody molecules bound to 
the surface of gold nanoparticles and enhance the capacity of the nanoparticles to bind the 
target protein, the amide bond between cysteamine and the active 7D3 antibody carboxylate 
groups was formed in solution. Next, the cysteamine-bound antibody was attached to the gold 
surface of the magnetic core nanoparticles via an Au-S bond. The unfunctionalized areas of 
the nanoparticles’ surface were backfilled with 1-butanethiol to prevent non-specific binding 
of interfering analytes and ensure the selectivity of the nanoparticles towards rHuEPO.  
 
Discussion 
Once functionalized and blocked, the magnetic core gold nanoparticles were then used to 
isolate rHuEPO from an aqueous solution. The binding of rHuEPO to the functionalized 
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nanoparticles was directly monitored by comparing the SERS spectra of the nanoparticles 
before and after interaction with the protein. The SERS spectrum of the functionalized 
nanoparticles before interaction with the protein is depicted in figure 4a. The Raman bands at 
565 cm
-1
, 752 cm
-1
 and 1549 cm
-1 
are characteristic of the antibody tryptophan residues [51-
54, 55]. The 960 cm
-1
 band represents a C-C stretching vibrational mode [51, 54] and the 
1062 cm
-1
 band may be attributed to a C–N stretching vibrational mode [51, 53, 56]. The 
characteristic band at 1203cm
-1
 arose from the phenylalanine and tyrosine residues in the 
antibody [51, 53, 56]. The 1425 cm
-1
 band may be attributed to the tyrosine residues and the 
CH vibrations of tryptophan indole rings within the antibody skeleton [51, 54]. Finally the 
band at 1584 cm
-1
 may be attributed to Tryptophan, Tyrosine, Phenylalanine residues [53, 55, 
58] while the band at 1611 cm
-1
 is due to Phenylalanine and amide I (α helix) vibration 
modes [51, 52, 57].  
The SERS spectrum of the functionalized nanoparticles after interaction with rHuEPO 
(Fig 4b) showed significant changes in spectral features that may be attributed to the binding 
event between the 7D3 antibody and the target protein [58]. The characteristic tryptophan 
Raman bands now appear at 786 cm
-1
, 871 cm
-1 
and 1584 cm
-1
 [51]. The band at 1437 cm
-1
 
may be attributed to CH2 scissoring vibration mode [51, 54, 55, 57]. The band at 1028 cm
-1
 
may be attributed to the in-plane ring CH deformation of the phenylalanine residues of the 
protein [51]. The low intensity of this band suggests that the phenyl ring approaches the gold 
surface of the nanoparticles but is not directly adsorbed onto the surface. Thus, the phenyl 
ring–nanoparticles interaction is weak [51]. The absence of the phenyl ring breathing 
vibration at 1002 cm
-1
 also suggests that the protein is not directly adsorbed onto the gold 
nanoparticles and the rHuEPO phenylalanine residues reside at a distance from the substrate’s 
gold surface [51].  
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The asymmetric vibrations (Cα CN and NH3
+
 deformation) of the CNH2 groups within the 
protein structure are expressed by the band at 1132 cm
-1
 [51, 53, 55, 56]. The amide III 
vibrations of the complex formed between the antibody and rHuEPO are indicated by two 
Raman bands at 1225 cm
-1
 and 1248 cm
-1
 [51, 52, 55, 57]. The weak band at 1523 cm
-1
 may 
attributed to the amide II vibration of antibody-rHuEPO complex [51, 53]. Despite the fact 
that the amide II band of proteins is Raman inactive, it may become enhanced when the 
protein structure is immobilized in a close proximity to the surface of a noble metal [51]. 
Finally, the amide I vibration of the antibody-EPO complex now appears at 1642 cm
-1
 [51-54, 
55, 57]. The spectral differences between the free functionalized nanoparticles and the 
rHuEPO-bound nanoparticles were used to monitor the binding event between the protein and 
the functionalized nanoparticles and, in effect, the selective isolation of the target protein 
from the sample matrix. This process is simple and does not require complex pretreatment 
and preconcentration procedures as in the case of other techniques, such as HPLC-MS.   
Direct SERS detection of rHuEPO  
To confirm the selective isolation of rHuEPO and to demonstrate the direct detection of 
the extracted protein by SERS, we used the functionalized nanoparticles to extract the protein 
from spiked horse plasma. The captured protein was then released from the nanoparticles’ 
surface using a releasing buffer [59]. The purified protein extract was then directly screened 
by SERS. The SERS spectra of the extracted protein and rHuEPO standard are depicted in 
figure 5a,b and show significant correlation. The SERS spectrum of the extracted rHuEPO 
(Fig. 5b) shows the characteristic Raman bands of a protein (Table 1).  
For cross-validation purposes, an aliquot of the protein extract was also screened by 
independent analytical services laboratory using ELISA. The ELISA screening confirmed 
that rHuEPO was present in the protein extract at concentration of 72 mIU/mL (553.7 
pg/mL).    
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Direct SERS detection of rHuEPO by handheld Raman spectrometer 
In order to demonstrate our methodology for the in-field screening of rHuEPO in 
biological matrices, we loaded the protein extract (from horse plasma) onto a commercial 
SERS substrate and used a handheld Raman spectrometer for the direct SERS detection of 
rHuEPO. The SERS spectra of the extracted protein and rHuEPO standard are depicted in 
figure 6a,b. The match between the two spectra is obvious. The measurements were carried 
out in the Raster Orbital Scanning (ROS) mode and took only one minute per sample to 
acquire the SERS spectrum. This sample scanning mode allows for scanning large area of the 
sample with a tightly focused laser beam. The ability to screen a large area of the sample 
increases the number of Raman-active molecules being probed by the excitation laser beam 
and, therefore, provides higher sensitivity data. The quality and the notable match in the 
SERS spectra (Fig. 6a,b) may be attributed to the ability of the ROS screening mode to 
acquire an average SERS spectrum from the entire sample load on the SERS substrate [43, 
60].  
In order to demonstrate the capacity of our protein analysis method, towards SERS 
quantification of rHuEPO, various concentrations of in the range of 50nM – 5 pM aqueous 
rHuEPO were employed. To each concentration of rHuEPO, a fresh substrate was used for 
the SERS quantification by the handheld Raman spectrometer. The laser power at the sample 
was 50 mW and a 5 second accumulation was carried out for each concentration. The band at 
1551 cm
-1 
was used a as a reference band for rHuEPO quantification. The SERS signals were 
found to decrease with decreasing concentration as indicated by Figure 7a.  A linear 
relationship was obtained between the SERS signal intensity at 1551 cm
−1
 and the 
corresponding rHuEPO log concentration plot is depicted in Figure 7b. As indicated by 
Figure 7b, close correlation (r
2
 = 0.995) was found over the concentration range of 50 nM to 
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5 pM rHuEPO. The minimum limit of detection was estimated mathematically using the 
regression equation in figure 7b and found to be 1 pM.     
In conclusion, we demonstrated the selective isolation and direct SERS detection of 
rHuEPO using antibody-functionalized nanoparticles and SERS. The changes in the SERS 
spectrum of the antibody-functionalized nanoparticles after their binding to a protein allow 
for monitoring the binding event by SERS. The direct SERS detection of extracted rHuEPO 
from a biological matrix is demonstrated for the first time. The SERS detection of the protein 
was supported by ELISA, which confirmed and quantified the rHuEPO in the protein extract. 
The iron core of the gold-coated nanoparticle plays a key role in the magnetically induced 
separation of rHuEPO from the matrix. However it does not play any operational role in the 
detection process of rHuEPO.  The burden of detection rests entirely on the plasmonic 
response of the Au shell and thus the detection mechanism is independent of whether the core 
is magnetic or not. Finally, the methodology was successfully utilized for the rapid in-field 
screening of rHuEPO within a biological matrix using a commercial SERS substrate and 
handheld Raman device. This study demonstrates a proof of concept for the combined 
selective isolation and in-field direct SERS detection of proteins in complex matrices. Our 
future work is directed towards reproducible direct SERS quantification of ultra-trace 
amounts of proteins in biological matrices using the demonstrated methodology and handheld 
spectrometer. 
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Figure legends 
Figure 1, TEM and histograms of a) iron oxide nanoparticles and b) magnetic core gold 
nanoparticles 
Figure 2, XRD of iron oxide nanoparticles  
Figure 3: UV-Vis absorption spectrum of magnetic core gold nanoparticles 
Figure 4: SERS spectrum of antibody-functionalized gold nanoparticles a) before and b) after 
binding with rHuEPO 
Figure 5: SERS spectrum of a) rHuEPO standard and b) rHuEPO extracted from horse 
plasma. Measurements were carried out on old-coated silicon nanopillars SERS substrate and 
using the inVia Renishaw Raman spectrometer.  
Figure 6: SERS spectrum of a) rHuEPO standard and b) rHuEPO extracted from horse 
plasma. Measurements were carried out on using handheld Raman spectrometer (1 minute 
measurement time per sample). Spectra were collected using 785 nm excitation wavelength 
and a single 40 second accumulation in the Raster Orbital Scanning (ROS) mode 
Figure 7: a) SERS spectra, at 1551 cm
-1
, of rHuEPO in the concentration range 50 nM to 5 
pM and b) Plot demonstrating the linear relationship between log concentration of rHuEPO 
and SERS intensity at 1551 cm
-1
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Graphical Abstract 
Schematic diagram of the selective protein isolation and detection by magnetic nanoparticles 
and portable Raman spectroscopy   
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Table 1, assignments of Raman bands in the SERS Spectra (Fig 5b) of r-HuEPO extracted 
from spiked horse plasma  
 
Raman shift (cm
-1
) Band assignment Reference 
1001 Benzene ring breathing of phenylalanine 52 
1149 ring stretch / νas(CαCN) 53, 57 
1176 Phenylalanine, Tyrosine  51, 55, 56 
1214 Phenylalanine 51, 58 
1245 Amide III 51, 57 
1286 Amide III 51 
1347 Tryptophan  51, 57 
1380 νas(COO
-
) 51, 53 
1468 CH2 (scissoring)  52, 53, 57 
1507 Phenylalanine, Histidine, Tryptophan 51, 55 
1534 Amide II 53 
1587 Tryptophan, Tyrosine, Phenylalanine 53, 56, 58 
1611 Amide I (α helix), Phenylalanine 51, 52, 57 
 
 
